Neuropathic Pain Market Size, Share, Top Manufacturers, Latest Trends, Future Prospects and Forecast 2027

                                        Neuropathic Pain Market

Neuropathic pain occurs when the somatosensory nerve system is damaged or diseased. This pain is linked to aberrant sensations known as dysesthesia, or pain from stimuli that are typically non-painful. It may have both continuous and episodic elements. The latter have the appearance of stabbings or electric shocks. It frequently results in nerve injury or nervous system dysfunction. Nerve damage can alter nerve function both at the location of the injury and in the surrounding tissues. Phantom limb syndrome, which is an uncommon disorder, is an example of neuropathic pain. It happens when a limb is removed due to disease or injury, but the brain still receives pain signals through the nerves that carry impulses from the missing limb. These nerves activate incorrectly, resulting in discomfort.


The most prevalent cause of neuropathic pain is diabetes. Because the incidence of painful diabetic neuropathy is 16 percent in the worldwide aged population suffering from diabetes, an increase in the geriatric population is predicted to stimulate demand for neuropathic pain treatment services. The worldwide Neuropathic Pain Market Analysis is predicted to rise due to an increase in the incidence of diabetes and cancer, approval of innovative treatment options for neuropathic pain, an increase in the number of pain management clinics, and an increase in demand for treatment of neuropathic pain. Other factors are fueling the market's fast expansion.


Market Segmentation:

By Drug Class

• Tricyclic Antidepressants

• Opioids

• Capsaicin Cream

• Steroids

• Others

By Indication

• Diabetic Neuropathy

• Spinal Stenosis

• Chemotherapy-induced Peripheral Neuropathy

By Distribution Channel

• Retail Pharmacies

• Hospital Pharmacies

• Online Pharmacies

• Others

Players in the market could expect profitable growth possibilities due to the high prevalence of neuropathic-like pain in psoriatic arthritis. Researchers from Cardiff University in the United Kingdom, for example, revealed in July 2019 that neuropathic-like pain as evidence of aberrant pain processing is widespread in people with psoriatic arthritis.

The major players operating in the global neuropathic pain market include, Pfizer, Inc., Johnson & Johnson Services, Inc., Sanofi S.A., Eily Lily and Company, GlaxoSmithKline PLC, Biogen Idec., Bristol-Myers Squibb, Baxter Healthcare Corporation, and Depomed, Inc.


Source Links:

https://www.globenewswire.com/en/news-release/2020/05/25/2038154/0/en/Neuropathic-Pain-Market-to-reach-US-9-862-3-Million-globally-by-2027-Coherent-Market-Insights.html

https://www.medgadget.com/2021/05/neuropathic-pain-market-report-2021-to-register-a-cagr-of-6-4-to-reach-us-9862-3-million-by-2027-global-industry-analysis-growth-size-companies-revenue.html